256 related articles for article (PubMed ID: 19010312)
21. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Gazvoda M; Beranič N; Turk S; Burja B; Kočevar M; Rižner TL; Gobec S; Polanc S
Eur J Med Chem; 2013 Apr; 62():89-97. PubMed ID: 23353746
[TBL] [Abstract][Full Text] [Related]
22. Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Zang T; Verma K; Chen M; Jin Y; Trippier PC; Penning TM
Chem Biol Interact; 2015 Jun; 234():339-48. PubMed ID: 25555457
[TBL] [Abstract][Full Text] [Related]
23. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Khanim F; Davies N; Veliça P; Hayden R; Ride J; Pararasa C; Chong MG; Gunther U; Veerapen N; Winn P; Farmer R; Trivier E; Rigoreau L; Drayson M; Bunce C
Br J Cancer; 2014 Mar; 110(6):1506-16. PubMed ID: 24569460
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Park AL; Lin HK; Yang Q; Sing CW; Fan M; Mapstone TB; Gross NL; Gumerlock MK; Martin MD; Rabb CH; Fung KM
Int J Clin Exp Pathol; 2010 Mar; 3(8):743-54. PubMed ID: 21151387
[TBL] [Abstract][Full Text] [Related]
25. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
26. Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system.
Azzarello J; Fung KM; Lin HK
J Histochem Cytochem; 2008 Sep; 56(9):853-61. PubMed ID: 18574251
[TBL] [Abstract][Full Text] [Related]
27. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Skarydová L; Zivná L; Xiong G; Maser E; Wsól V
Chem Biol Interact; 2009 Mar; 178(1-3):138-44. PubMed ID: 19007764
[TBL] [Abstract][Full Text] [Related]
28. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Lewis MJ; Wiebe JP; Heathcote JG
BMC Cancer; 2004 Jun; 4():27. PubMed ID: 15212687
[TBL] [Abstract][Full Text] [Related]
29. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
Wang S; Yang Q; Fung KM; Lin HK
Mol Cell Endocrinol; 2008 Jul; 289(1-2):60-6. PubMed ID: 18508192
[TBL] [Abstract][Full Text] [Related]
30. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.
Penning TM
Expert Opin Ther Pat; 2017 Dec; 27(12):1329-1340. PubMed ID: 28895472
[TBL] [Abstract][Full Text] [Related]
31. Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity.
Matsuura K; Shiraishi H; Hara A; Sato K; Deyashiki Y; Ninomiya M; Sakai S
J Biochem; 1998 Nov; 124(5):940-6. PubMed ID: 9792917
[TBL] [Abstract][Full Text] [Related]
32. New enzymatic assay for the AKR1C enzymes.
Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
[TBL] [Abstract][Full Text] [Related]
33. Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Mantel A; Carpenter-Mendini A; VanBuskirk J; Pentland AP
Exp Dermatol; 2014 Aug; 23(8):573-8. PubMed ID: 24917395
[TBL] [Abstract][Full Text] [Related]
34. Stereospecific reduction of 5β-reduced steroids by human ketosteroid reductases of the AKR (aldo-keto reductase) superfamily: role of AKR1C1-AKR1C4 in the metabolism of testosterone and progesterone via the 5β-reductase pathway.
Jin Y; Mesaros AC; Blair IA; Penning TM
Biochem J; 2011 Jul; 437(1):53-61. PubMed ID: 21521174
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the major single nucleotide polymorphic variants of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase).
Detlefsen AJ; Wangtrakuldee P; Penning TM
J Steroid Biochem Mol Biol; 2022 Jul; 221():106121. PubMed ID: 35489629
[TBL] [Abstract][Full Text] [Related]
36. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
37. Structure of AKR1C3 with 3-phenoxybenzoic acid bound.
Jackson VJ; Yosaatmadja Y; Flanagan JU; Squire CJ
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Apr; 68(Pt 4):409-13. PubMed ID: 22505408
[TBL] [Abstract][Full Text] [Related]
38. Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Winkler JD; Penning TM
Bioorg Med Chem Lett; 2011 Mar; 21(5):1464-8. PubMed ID: 21277203
[TBL] [Abstract][Full Text] [Related]
39. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3).
Brozic P; Golob B; Gomboc N; Rizner TL; Gobec S
Mol Cell Endocrinol; 2006 Mar; 248(1-2):233-5. PubMed ID: 16337332
[TBL] [Abstract][Full Text] [Related]
40. Role of aldo-keto reductase enzymes in mediating the timing of parturition.
Byrns MC
Front Pharmacol; 2011; 2():92. PubMed ID: 22291648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
